drugset / Trial / NCT03468413
A First-in-human Phase 1 Study of CP1050
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase I, first-in-human, double-blind, single-centre, randomised, placebo-controlled, single and multiple oral dose study in healthy subjects conducted in 4 parts (Part 1; Single-ascending dose, Part 2; Food-effect evaluation, Part 3; Gender-effect evaluation, Part 4; Multiple-ascending dose).
Timeline
- Start
- 2018-02-05
- Primary completion
- 2018-08
- Completion
- 2019-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CP1050 | Unknown | — | Oral |
Indications
No indication recorded.